Table 1.

Clinical trial patient characteristics

PatientSexAge, yRaceKPSWHO scoreIDH-1/2 mutationMGMT promoter methylationPFS (diagnosis)OS (diagnosis)RPA predicted classRPA O-E
1M55W90110.121.7IV10.6
2M55W80164.0a64.0bIV52.9
3M53W901N/A61.9a61.9bIV50.8
4M47H1000+60.7a60.7bIII42.8
5F60W1000+59.0a59.0bIV47.9
6F55W90120.033.4IV22.3
7M67W901+25.346.5IV35.4
8F63W801+11.624.2IV13.1
9M57W901+29.241.1IV30
10M55W80114.321.6IV10.5
11M59W80111.019.7IV8.6
Median5590125.341.1IV30
  • NOTE: Demographic and prognostics factors for patients with newly diagnosed glioblastoma and corresponding PFS and OS from the time of surgery (histologic diagnosis). Patients shown were those able to complete the predefined study therapy (completion of DI-TMZ cycle 1 and DC vaccines 1–3). Observed and predicted survival times are expressed in months. RPA O-E is the difference between the observed survival and the survival predicted on the basis of the RPA suggested by Curran and colleagues (24). For class III, the predicted median survival is 17.9 months, whereas for class IV, the predicted median survival is 11.1 months.

  • Abbreviations: H, Hispanic; NA, tissue not available; O–E, observed–expected survival months; W, white.

  • aNo progression.

  • bAlive.